Offer Update and Appendix 3B
Released
Released
Announcement PDF
IMAGION BIOSYSTEMS LIMITED
®
(ASX: IBX)
08 November 2019
Quotation of options and extension of closing date
MELBOURNE - Imagion Biosystems Limited (ASX: IBX) (the Company) refers to its renounceable
pro rata rights issue offer of new fully paid ordinary shares (New Shares) announced on 28
October 2019 (Rights Issue). Under the Rights Issue, each subscriber will receive, for every 2
New Shares subscribed, 1 new free attaching option exercisable into a fully paid ordinary share at
$0.05, expiring 2 years from its date of issue (New Option).
The Company lodged a prospectus with ASIC and ASX in relation to the Rights Issue on 28
October 2019.
The Company has now determined to vary the Rights Issue offer by seeking quotation of the New
Options on the ASX, and extending the closing date of the offer. Accordingly, the Company has
today lodged with ASIC and ASX a supplementary prospectus dated 8 November 2019, which sets
out the variations.
Quotation of New Options
Attached to this announcement is Appendix 3B seeking quotation of the New Options. The
Company has previously applied for quotation of the New Shares under an Appendix 3B dated 28
October 2019.
New Timetable
The revised indicative timetable for the Rights Issue offer is as follows:
Closing date for acceptances
19 November 2019
Notify ASX of under-subscriptions
22 November 2019
Anticipated date for issue of New Shares and New Options
26 November 2019
Dispatch of securityholding statements
27 November 2019
Normal trading of New Shares and New Options expected to commence
Note: The Directors may extend the Closing Date by giving at least 3 Business Days’ notice to ASX prior to the Closing
Date, subject to the Corporations Act and Listing Rules. As such the date the New Shares are expected to commence
trading on ASX may vary.
Further Information:
Email the Company at: corpsecretary@imagionbio.com
- ENDS
Imagion Biosystems Limited
ACN 616 305 027
Level 8, 555 Bourke Street, Melbourne VIC 3000
www.imagionbiosystem.com
®
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology.
Combining biotechnology and nanotechnology the Company aims to detect cancer and other
diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed
on the Australian Securities Exchange (ASX) in June 2017.
For further information please visit www.imagionbiosystems.com
U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630
Australian Media & Investor Relations:
Kyahn Williamson, WE Buchan
ImagionBiosystems@we-buchan.com
+61-3-9866-4722
Imagion Biosystems Limited
ACN 616 305 027
Level 8, 555 Bourke Street, Melbourne VIC 3000
www.imagionbiosystem.com
Appendix 3B
New issue announcement
Rule 2.7, 3.10.3, 3.10.4, 3.10.5
Appendix 3B
New issue announcement,
application for quotation of additional securities
and agreement
Information or documents not available now must be given to ASX as soon as available. Information
and documents given to ASX become ASX’s property and may be made public.
Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12,
04/03/13
Name of entity
IMAGION BIOSYSTEMS LIMITED (the Company)
ABN
42 616 305 027
We (the entity) give ASX the following information.
Part 1 - All issues
You must complete the relevant sections (attach sheets if there is not enough space).
1
+Class of +securities issued or to
be issued
Options each to acquire one fully paid ordinary
share (New Options)
2
Number of +securities issued or
to be issued (if known) or
maximum number which may be
issued
The Company will issue a maximum of
163,684,692 New Options pursuant to a
renounceable pro-rata rights issue (Rights
Issue) as detailed in the ASX Announcement
released by the Company on 28 October 2019.
The New Options will be issued as free attaching
options (on a 1-for-2 basis) to the maximum of
327,369,384 new fully paid ordinary shares
(New Shares) being offered under the Rights
Issue. The Company applied to the ASX for the
quotation of the New Shares under an Appendix
3B dated 28 October 2019.
3
Principal terms of the +securities
(e.g. if options, exercise price
and expiry date; if partly paid
+securities,
the
amount
outstanding and due dates for
+convertible
payment;
if
securities, the conversion price
and dates for conversion)
The New Options are each exercisable into a
fully paid ordinary share (Share) at $0.05, on or
before the date that is 2 years from their date of
issue.
Do the +securities rank equally
in all respects from the +issue
date with an existing +class of
The Company intends to apply for quotation of
the New Options, and the New Options will form
a new class of quoted securities.
4
For further details on the terms of the New
Options, refer to the Company’s Prospectus
dated 28 October 2019 and Supplementary
Prospectus dated 8 November 2019.
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 1
Appendix 3B
New issue announcement
5
quoted +securities?
If the additional +securities do
not rank equally, please state:
• the date from which they do
• the extent to which they
participate for the next
dividend, (in the case of a
trust, distribution) or interest
payment
• the extent to which they do
not rank equally, other than
in relation to the next
dividend,
distribution
or
interest payment
Shares issued on exercise of the New Options
will rank equally in all respects with the existing
Shares in the Company.
Issue price or consideration
Nil cash consideration. The New Options will be
issued as free attaching options to New Shares
on a 1-for-2 basis.
Each New Option has an exercise price of $0.05.
6
Purpose of the issue
(If issued as consideration for
the acquisition of assets, clearly
identify those assets)
The funds raised under the Rights Issue at the
targeted amount are proposed to primarily be
expended to prepare for and conduct a human
study of its MagSense instrument and formulated
nanoparticle, and otherwise for general working
capital purposes.
6a
Is the entity an +eligible entity
that has obtained security
holder approval under rule
7.1A?
Yes
If Yes, complete sections 6b –
6h in relation to the +securities
the subject of this Appendix 3B,
and comply with section 6i
6b
The date the security holder
resolution under rule 7.1A was
passed
31 May 2019
6c
Number of +securities issued
without security holder approval
under rule 7.1
N/A
6d
Number of +securities issued
with security holder approval
under rule 7.1A
N/A
6e
Number of +securities issued
with security holder approval
under rule 7.3, or another
specific security holder approval
(specify date of meeting)
N/A
Appendix 3B
New issue announcement
6f
Number of +securities issued
under an exception in rule 7.2
163,684,692 New Options
6g
If +securities issued under rule
7.1A, was issue price at least
75% of 15 day VWAP as
calculated under rule 7.1A.3?
Include the +issue date and both
values. Include the source of
the VWAP calculation.
N/A
6h
If +securities were issued under
rule
7.1A
for
non-cash
consideration, state date on
which valuation of consideration
was released to ASX Market
Announcements
N/A
6i
Calculate the entity’s remaining
issue capacity under rule 7.1
and rule 7.1A – complete
Annexure 1 and release to ASX
Market Announcements
See Annexure 1
7
+Issue dates
26 November 2019
Note: The issue date may be prescribed by
ASX (refer to the definition of issue date in rule
19.12). For example, the issue date for a pro
rata entitlement issue must comply with the
applicable timetable in Appendix 7A.
Cross reference: item 33 of Appendix 3B.
Number
8
9
Number and +class of all
+securities quoted on ASX
(including the +securities in
section 2 if applicable)
+class
Number and
of all
+securities not quoted on ASX
(including the +securities in
section 2 if applicable)
Maximum of
654,738,768
+Class
Fully paid ordinary
Shares
(This number also includes the
maximum number of New
Shares
(327,369,384
New
Shares) that may be issued
under the Rights Issue, for which
the Company applied to the ASX
for quotation under an Appendix
3B dated 28 October 2019)
Maximum of
163,684,692
The New Options are each
exercisable into a Share at
$0.05, on or before the date of 2
years from their date of issue
Number
+Class
Performance Rights
10,750,000
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 3
Appendix 3B
New issue announcement
5,112,500
Options: Exercisable at $0.028
and expiring on the earlier of
24/06/2024 or 30 days after the
cessation of employment.
3,000,000
Options: Exercisable at $0.20
expiring on 20 June 2021
34,700,000
Options: Exercisable at $0.06
expiring on 27 November 2020
2,017,553
Employee Options: Exercisable
at various exercise prices
between $0.0256 and $0.0302
with varying expiry dates
between
28/02/2021
and
30/06/2021.
Advisory
Board
Options:
Exercisable at $0.06, vesting
quarterly over two years with
varying expiry dates between
22/08/2024 and 7/10/2024.
600,000
10
Dividend policy (in the case of a
trust, distribution policy) on the
increased capital (interests)
N/A
Part 2 - Pro rata issue
11
Is security
required?
holder
12
Is the issue renounceable or
non-renounceable?
Renounceable
13
Ratio in which the +securities
will be offered
1 New Share for every 1 Share held
14
+Class
of +securities to which
the offer relates
Fully Paid Ordinary Shares
15
+Record
Thursday, 31 October 2019
16
Will holdings on different
registers (or sub registers) be
aggregated
for
calculating
entitlements?
No
17
Policy for deciding entitlements
in relation to fractions
Not required
date
entitlements
to
approval
determine
No
Appendix 3B
New issue announcement
18
Names of countries in which the
entity has security holders who
will not be sent new offer
documents
Germany, Hong Kong, Malaysia, Singapore,
United Arab Emirates and United Kingdom
Note: Security holders must be told how their
entitlements are to be dealt with.
Cross reference: rule 7.7.
19
Closing date for receipt of
acceptances or renunciations
Thursday, 7 November 2019
20
Names of any underwriters
N/A
21
Amount of any underwriting fee
or commission
N/A
22
Names of any brokers to the
issue
CPS Capital Group Pty Ltd
23
Fee or commission payable to
the broker to the issue
$60,000 plus 1% of the total amount raised, plus
5% on any amounts placed by the broker, plus
6,000,000 options on the same terms as the New
Options.
24
Amount of any handling fee
payable to brokers who lodge
acceptances or renunciations
on behalf of security holders
N/A
25
If the issue is contingent on
security holders’ approval, the
date of the meeting
N/A
26
Date
entitlement
and
acceptance form and offer
documents will be sent to
persons entitled
Tuesday, 5 November 2019
27
If the entity has issued options,
and the terms entitle option
holders to participate on
exercise, the date on which
notices will be sent to option
holders
N/A
28
Date rights trading will begin (if
applicable)
Wednesday, 30 October 2019
29
Date rights trading will end (if
applicable)
Thursday, 7 November 2019
30
How do security holders sell
their entitlements in full through
The rights to Shares under the Offer are
renounceable. Accordingly, holders may trade
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 5
Appendix 3B
New issue announcement
a broker?
their rights on ASX and dispose of their rights to
subscribe for Shares to any other party.
If a holder wishes to sell their Entitlement, they
can complete the form attached to the
Prospectus.
31
How do security holders sell
part of their entitlements
through a broker and accept for
the balance?
As above.
32
How do security holders
dispose of their entitlements
(except by sale through a
broker)?
N/A
33
+Issue date
Tuesday, 26 November 2019
Part 3 - Quotation of securities
You need only complete this section if you are applying for quotation of securities
34
Type of +securities
(tick one)
(a)
+Securities described in Part 1
(b)
All other +securities
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid,
employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible
securities
Entities that have ticked box 34(a)
Additional securities forming a new class of securities
Tick to indicate you are providing the information or
documents
35
If the +securities are +equity securities, the names of the 20 largest holders of
the additional +securities, and the number and percentage of additional
+securities held by those holders
36
If the +securities are +equity securities, a distribution schedule of the additional
+securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over
Appendix 3B
New issue announcement
A copy of any trust deed for the additional +securities
37
Entities that have ticked box 34(b)
38
Number of +securities for which
+quotation is sought
39
+Class
40
Do the +securities rank equally in
all respects from the +issue date
with an existing +class of quoted
+securities?
of +securities for which
quotation is sought
If the additional +securities do not
rank equally, please state:
• the date from which they do
• the extent to which they
participate for the next
dividend, (in the case of a
trust, distribution) or interest
payment
• the extent to which they do not
rank equally, other than in
relation to the next dividend,
distribution
or
interest
payment
41
Reason for request for quotation
now
Example: In the case of restricted securities, end
of restriction period
(if issued upon conversion of
another +security, clearly identify
that other +security)
Number
42
+Class
+class
Number and
of all
+securities
quoted on ASX
(including the +securities in clause
38)
Quotation agreement
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 7
Appendix 3B
New issue announcement
Quotation of our additional +securities is in ASX’s absolute discretion. ASX may
quote the +securities on any conditions it decides.
1
+
2
We warrant the following to ASX.
•
The issue of the +securities to be quoted complies with the law and is not for
an illegal purpose.
•
There is no reason why those +securities should not be granted +quotation.
•
An offer of the +securities for sale within 12 months after their issue will not
require disclosure under section 707(3) or section 1012C(6) of the
Corporations Act.
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this
warranty
•
Section 724 or section 1016E of the Corporations Act does not apply to any
applications received by us in relation to any +securities to be quoted and that
no-one has any right to return any +securities to be quoted under sections
737, 738 or 1016F of the Corporations Act at the time that we request that
the +securities be quoted.
•
If we are a trust, we warrant that no person has the right to return the
+securities to be quoted under section 1019B of the Corporations Act at the
time that we request that the +securities be quoted.
3
We will indemnify ASX to the fullest extent permitted by law in respect of any claim,
action or expense arising from or connected with any breach of the warranties in this
agreement.
4
We give ASX the information and documents required by this form. If any information
or document is not available now, we will give it to ASX before +quotation of the
+securities begins.
We acknowledge that ASX is relying on the information and
documents. We warrant that they are (will be) true and complete.
Jovanka Naumoska
Company Secretary
8 November 2019
Share your feedback
Discover